Table 2 Ten most common ART regimens purchased in 2016; n = 1524 (76.4% of the total sample of 1995 participants)
Regimen | N = 1524 n (%) |
|---|---|
dolutegravir/abacavir/lamivudine | 419 (27.5%) |
elvitegravir/cobicistat/TAF/emtricitabine | 256 (16.8%) |
efavirenz/TDF/emtricitabine | 207 (13.6%) |
rilpivirine/TDF/emtricitabine | 190 (12.5%) |
dolutegravir + TDF/emtricitabine | 132 (8.7%) |
raltegravir + TDF/emtricitabine | 81 (5.3%) |
nevirapine + TDF/emtricitabine | 78 (5.1%) |
elvitegravir/cobicistat/TDF/emtricitabine | 61 (4.0%) |
nevirapine + abacavir/lamivudine | 59 (3.9%) |
r/Atazanavir + TDF/emtricitabine | 41 (2.7%) |